報價延遲最少15分鐘:2025/07/16 06:57 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.88
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.50/-1.61
|
|
企業價值
1.01B
|
| 資產負債 |
|
每股賬面淨值
4.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
76.30M
|
|
每股收益
6.17
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/16 06:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
